Gastroenterology Research and Practice / 2019 / Article / Tab 2

Research Article

Renal Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Patients with Liver Cirrhosis: A Nationwide Cohort Study

Table 2

Multivariate Cox proportional hazards model analysis of risk of ESRD after adjustment for competing mortality.

HR (95% CI) value

ACEi/ARB vs. CCB users1.15 (0.69–1.94)0.591
Age0.98 (0.96–1.00)0.040
Male vs. female1.02 (0.59–1.80)0.932
Hepatitis B virus infection0.71 (0.28–1.82)0.481
Hepatitis C virus infection0.73 (0.28–1.90)0.522
Alcoholic liver disease0.20 (0.03–1.40)0.104
Other chronic hepatitis0.73 (0.42–1.27)0.267
Hypertension1.82 (0.57–5.74)0.309
Diabetes mellitus2.49 (1.29–4.82)0.007
Congestive heart failure1.31 (0.53–3.27)0.559
Hyperlipidemia1.25 (0.69–2.25)0.465
Beta-blockers0.71 (0.38–1.32)0.278
Statin1.14 (0.50–2.61)0.760
Metformin0.86 (0.44–1.68)0.664
Aspirin0.94 (0.49–1.81)0.858
NSAIDs or COX-20.51 (0.29–0.91)0.022

ACEi: angiotensin-converting enzyme inhibitor; ARB: angiotensin receptor blocker; CCB: calcium channel blocker; CI: confidence interval; COX-2: cyclooxygenase-2 inhibitor; ESRD: end-stage renal disease; HR: hazard ratio; NSAIDs: nonsteroidal anti-inflammatory drugs.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.